AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 04, 2023 07:00 ET
|
AC Immune SA
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateReceived FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat...
RaceTrac’s Run For Research 5K Returns to Truist Park September 16
August 03, 2023 14:00 ET
|
Racetrac, Inc.
ATLANTA, GA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- According to The Michael J. Fox Foundation for Parkinson’s Research (MJFF), six million people worldwide live with Parkinson’s disease. One million of...
AC Immune SA Appoints New Chief Medical Officer
July 26, 2023 07:00 ET
|
AC Immune SA
AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:...
NysnoBio Awarded Michael J. Fox Foundation Grant to Advance Parkin Gene Therapy
July 17, 2023 16:05 ET
|
NysnoBio LLC
- The funding will support NB001 Parkin gene replacement therapy IND-enabling studies- Initial indication in a substantial, genetically defined Parkinson’s population: Parkin-PD- Parkin-PD mutations...
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease
July 17, 2023 07:00 ET
|
Athira Pharma, Inc.
New preclinical data demonstrate neuroprotective effects of fosgonimeton in models of amyloid-ß-mediated toxicity In preclinical models, ATH-1105 protects against pathologies common to amyotrophic...
AC Immune Holds Annual General Meeting of Shareholders
June 23, 2023 16:30 ET
|
AC Immune SA
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ:...
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
April 28, 2023 07:00 ET
|
AC Immune SA
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer’s disease...
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
March 28, 2023 01:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., March 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
March 16, 2023 07:00 ET
|
AC Immune SA
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein...
NKGen Biotech Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Natural Killer Cell Therapies Targeting Neurodegenerative Diseases
March 08, 2023 13:27 ET
|
NKGen Biotech
SANTA ANA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...